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Abstract
Functional evidence suggests that nitric oxide (NO) signalling in the rostral ventrolateral medulla (RVLM) is
cGMP-dependent and that this pathway is impaired in hypertension. We examined cGMP expression as a
marker of active NO signalling in the C1 region of the RVLM, comparing adult (>18 weeks) Wistar-Kyoto
(WKY, n = 4) and spontaneously hypertensive rats (SHR, n = 4). Double label immunohistochemistry for
cGMP-immunoreactivity (IR) and C1 neurons [as identified by phenylethanolamine N-methyltransferase
(PNMT-IR) or tyrosine hydroxylase TH-IR)], or neuronal NO synthase (nNOS) neurones, failed to reveal
cGMP-IR neurons in the RVLM of either strain, despite consistent detection of cGMP-IR in the nucleus
ambiguus (NA). This was unchanged in the presence of isobutylmethylxanthine (IBMX; 0.5 mM, WKY, n =
4, SHR n = 2) and in young animals (WKY, 10-weeks, n = 3). Incubation of RVLM-slices (WKY, 10-weeks, n
= 9) in DETA-NO (100 μm; 10 min) or NMDA (10 μM; 2 min) did not uncover cGMP-IR. In all studies,
cGMP was prominent within the vasculature. Soluble guanylate cyclase (sGC)-IR was found throughout
neurones of the RVLM, but did not co-localise with PNMT, TH or nNOS-IR neurons (WKY, 10-weeks, n =
6). Results indicate that within the RVLM, cGMP is not detectable using immunohistochemistry in the basal
state and cannot be elicited by phosphodiesterase inhibition, NMDA receptor stimulation or NO donor
application.
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Abstract Functional evidence suggests that nitric oxide
(NO) signalling in the rostral ventrolateral medulla
(RVLM) is cGMP-dependent and that this pathway is
impaired in hypertension. We examined cGMP expression
as a marker of active NO signalling in the C1 region of the
RVLM, comparing adult ([18 weeks) Wistar–Kyoto
(WKY, n = 4) and spontaneously hypertensive rats (SHR,
n = 4). Double label immunohistochemistry for cGMP-
immunoreactivity (IR) and C1 neurons [as identified by
phenylethanolamine N-methyltransferase (PNMT-IR) or
tyrosine hydroxylase TH-IR)], or neuronal NO synthase
(nNOS) neurones, failed to reveal cGMP-IR neurons in the
RVLM of either strain, despite consistent detection of
cGMP-IR in the nucleus ambiguus (NA). This was
unchanged in the presence of isobutylmethylxanthine
(IBMX; 0.5 mM, WKY, n = 4, SHR n = 2) and in young
animals (WKY, 10-weeks, n = 3). Incubation of RVLM-
slices (WKY, 10-weeks, n = 9) in DETA-NO (100 lm;
10 min) or NMDA (10 lM; 2 min) did not uncover cGMP-
IR. In all studies, cGMP was prominent within the vascu-
lature. Soluble guanylate cyclase (sGC)-IR was found
throughout neurones of the RVLM, but did not co-localise
with PNMT, TH or nNOS-IR neurons (WKY, 10-weeks,
n = 6). Results indicate that within the RVLM, cGMP is
not detectable using immunohistochemistry in the basal
state and cannot be elicited by phosphodiesterase inhibition,
NMDA receptor stimulation or NO donor application.
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Introduction
The rostral ventrolateral medulla (RVLM) contributes sig-
nificant excitatory drive to sympathetic preganglionic
neurons and therefore also to vascular tone via two well
characterised subpopulations of bulbospinal neurons: the
C1 (adrenergic) and non-C1 cell groups [1–3]. Glutamate is
the major neurotransmitter driving the activity of these
neurons [3, 4], but the gaseous neurotransmitter nitric oxide
(NO) is thought to play a key role in regulating glutamate
induced pressor responses, and therefore modulating
homeostatic blood pressure mechanisms [5–7]. Altered NO
signalling in the RVLM is associated with increased sym-
pathetic outflow in animal models of hypertension [8],
however the mechanism of action is unclear, with a range of
effects consistent with NO-mediated pressor, depressor or
neutral effects being reported [9–11].
One of the most widely studied and best-understood NO
second messenger systems is the activation of soluble
guanylate cyclase (sGC) and the subsequent generation of
intracellular 30,50-cyclic guanosine monophosphate
(cGMP) [12, 13]. Soluble GC is a heme-containing
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heterodimer of a and b subunits, with the b1 subunit being
the major subunit, as there is no catalytic activity in its’
absence [14, 15]. Activation of NMDA receptors can drive
this pathway, with increased intracellular Ca2+ stimulating
the Ca2+/calmodulin NO system, promoting conversion of
L-Arginine to NO. Intracellular cGMP levels can also be
regulated by membrane bound, or particulate guanylyl
cyclases, incorporating the receptors for atrial (ANP), brain
(BNP) and C-type (CNP) natriuretic peptides [13]. As a
second messenger, cGMP can target various protein kina-
ses and ion channels, and its activity is limited through
degradation by phosphodiesterases (PDE) [13].
Nitric oxide has alternative neuromodulatory mecha-
nisms. This includes the S-nitrosylation of proteins and in
particular that of NMDA receptors [12], and interactions
with superoxide, with the resultant peroxynitrite having
potent oxidising properties that convey a variety of phys-
iological and pathophysiological effects [16].
Within the RVLM, all three NO synthase (NOS) iso-
forms are present [17] and we have shown recently that
neuronal (n)NOS is increased in the RVLM of spontane-
ously hypertensive rats (SHR) [18]. Work by Chan et al.
[19] suggests that the relative balance of functional nNOS
versus inducible (i)NOS activity determines RVLM output,
and further, that the different NOS isoforms activate dif-
ferent downstream signals, with nNOS driving sGC/cGMP-
dependent sympathoexcitatory responses, and NO pro-
duced by iNOS driving peroxynitrite formation and
sympathoinhibitory responses [20]. Glutamate-induced
pressor responses in the RVLM are in general proposed to
be modulated by NO-sGC/cGMP [5, 6, 21] and this is
supported by electrophysiological studies showing cGMP-
dependent potentiation of glutamate currents in RVLM
slice preparations [7].
To date, no studies have described the immunohisto-
chemical localisation of neurons capable of expressing
cGMP within the C1 region [22]. Given the strong evi-
dence that NO signalling plays a functional role in the
RVLM, we sought to identify the cellular targets for NO in
the RVLM, visualising cGMP and its neuroanatomical
relationship with the C1 cell group, as identified by the
presence of tyrosine hydroxylase (TH) or phenylethanola-
mine N-methyltransferase (PNMT), and the more medially
located nNOS expressing cell population [18, 23]. Given
that studies in SHR show augmented pressor responses to
microinjection of glutamate in the RVLM [24, 25], we
considered the hypothesis that the NO downstream sig-
nalling sGC/cGMP pathway may be altered. We therefore
also sought to examine if altered cGMP expression, as
determined using fluorescence immunohistochemistry, was
demonstrable in the RVLM of the SHR when compared its
genetic control, the Wistar Kyoto (WKY). An inability to
detect cGMP-immunoreactivity (-IR) in the RVLM of
either strain led to additional studies that sought to increase
synthesis of cGMP in fresh RVLM brain slices, and
examine sGC-IR throughout the region.
Materials and methods
Animals
Animals were obtained from the Animal Resources Centre,
Murdoch, Western Australia and all procedures conformed
to the guidelines approved by the Murdoch University
Animal Ethics Committee. Rats were housed on a 12 h
light-dark cycle with access to standard rat chow and water
ad libitum. Male rats were used in all experiments. Wistar–
Kyoto (n = 26 in total) and SHR (n = 8 total) animals
were used in the different age groups as detailed in each
experimental protocol.
Animal tissue preparation for immunohistochemistry
Rats were anaesthetised with sodium pentobarbitone
(Thiobarb, Jurox, Rutherford, Australia; 100 mg/kg)
administered intraperitoneally. A pre-fixation solution of
ice-cold heparinised saline (30 ml, 0.9% NaCl containing
2,000 I.U. of heparin [Jurox, Rutherford, Australia]) was
perfused via the ascending aorta (6 ml per minute), fol-
lowed by 180 ml of ice-cold 3.7% formalin diluted in 0.9%
saline at the same rate. In one set of experiments, the
phosphodiesterase inhibitor isobutylmethylxanthine
(IBMX; 0.5 mM Sigma, St. Louis, MO) was added to the
pre-fixation saline solution. Brains were removed and post
fixed in 4% formalin for 4 h at 4C. Tissue was washed in
0.1 M phosphate buffered saline (PBS, pH 7.4)
(3 9 10 min) and coronal hindbrain sections (50 lm)
sections were cut using a vibrating microtome (Vibratome,
St. Louis, MO). Sections were split into two alternate
series, with each section therefore 100 lm apart. Sections
were then incubated in 50% ethanol for 30 min and then
washed in 0.01 M PBS containing 10 mM Tris (TPBS;
2 9 15 min).
Animal tissue preparation for brainstem slice in-vitro
incubation
Animals were anaesthetised and perfused as for the immu-
nohistochemical experiments. Perfusate consisted of ice-cold
sucrose based cutting solution (2 mM KCl, 2 mM MgSO4,
1.25 mM NaH2PO4, 1 mM MgCl2, 26 mM NaHCO3,
0.1 mM CaCl2, 10 mM D-glucose, 248 mM sucrose, 95% O2/
5% CO2, pH 7.4 [26] containing IBMX (0.5 mM) and heparin
1,000 U/ml (Jurox). The brains were removed immediately
and coronal RVLM sections (400 lm) were cut on a vibrating
802 J Biomed Sci (2008) 15:801–812
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microtome while immersed in the same ice-cold sucrose
cutting solution.
After cutting, brain slices were warmed to 37C over
20 min in an artificial cerebrospinal fluid (aCSF) solution
(124 mM NaCl, 2 mM KCl, 2 mM MgSO4  7H2O,
1.25 mM NaH2PO4, 26 mM NaHCO3, 2 mM CaCl2,
10 mM D-glucose, 0.5 mM IBMX, 95% O2/5% CO2, pH
7.4) [26]. Once at 37C, slices were incubated for a further
30 min, prior to incubation in either 100 lM NMDA
(Sigma) plus 10 lM glycine for 1 9 5 min [27] or 100 lM
DETA-NO (Sigma) for 1 9 15 min [28] in aCSF solution.
Twenty minutes prior to use, DETA-NO was prepared in
aCSF buffer and warmed to 37C to stabilise NO release.
Submerging the slices in ice-cold 3.7% formalin terminated
the reaction. Control slices were incubated in aCSF solu-
tion only. Slices were post-fixed for 2 h in 3.7% formalin at
4C, followed by washing in 0.1 M PBS (1 9 30 min).
Slices were then cryoprotected in 30% sucrose in 0.1 M
PBS and sodium azide (NaN3, 0.1%; overnight) prior to
cutting 50 lm sections on a cryostat (Leica CM1510; Leica
Microsystems GmbH, Wetzlar, Germany) at -17C for
subsequent immunohistochemistry using alternate sections
as described above.
Immunohistochemistry
Sections were pre-treated for one hour at room temperature
in blocking solution containing 10% donkey serum
(Chemicon, Temecula, CA), diluted in TPBS with 0.3%
Triton-X (Tx) and 0.1% NaN3. They were then incubated
free floating in different combinations of primary antibody
[cGMP/nNOS, cGMP/PNMT or TH, sGC/nNOS, sGC/
PNMT, sGC/Protein Gene Product (PGP9.5) or sGC/glial
fibrillary acidic protein (GFAP)] at pre-optimised concen-
trations (Table 1) for 24 h at room temperature, then 72–
96 h at 4C. From each animal, the RVLM was split into
two series of alternating sections, allowing two different
antibody combinations per animal. Antibodies were diluted
in blocking solution. Sections were then washed
(3 9 30 min TPBS) and incubated with species specific
secondary antibodies (Table 1) for 12–14 h at 4C, diluted
in TPBS with 0.3% Tx, 0.1% NaN3 and 1% donkey serum.
Finally, sections were washed (3 9 30 min TPBS),
mounted on slides and cover slipped with ProLong Antif-
ade (Molecular Probes, Eugene, OR USA).
The RVLM region examined was defined as that area
extending caudally 600–800 lm from the caudal pole of
the facial nucleus. This corresponds to -12.5 to -11.7 mm
from Bregma [29] bounded laterally by the spinal trigem-
inal tract, medially by the inferior olive and pyramids, and
dorsally by the compact formation of the NA. Sections
were arranged in a rostro-caudal orientation prior to
mounting and all sections were examined bilaterally for
immunostaining. The NA from each series of sections was
used as an internal control for cGMP-IR as it consistently
demonstrated neuronal expression.
Control experiments
For negative controls, RVLM tissue sections were incu-
bated in blocking solution alone (no antibody controls) and
run in parallel to each of the experimental protocols.
Positive control experiments for the cGMP, sGC and
PGP9.5 antibodies were performed using additional sec-
tions from animals used in the experiments described
above. For sGC, sections of cerebellum were processed in
parallel to RVLM sections. A TH/PGP9.5 double label
combination was used as a positive control for the PGP9.5
antibody. To confirm that the cGMP antibody was detect-
ing both neuronal and vascular elements, a cGMP/mouse
anti alpha-smooth muscle actin (alpha-SMA) double label
combination was used (Table 1).
Previous studies and manufacturers product information
have documented the specificity of antibody reactions and/
or characteristic staining patterns for the cGMP [30, 31],
nNOS [32], sGC [33], PNMT [34], TH [35], PGP-9.5 [36,
37], GFAP [38] and SMA [39] antibodies.
Imaging and analysis
A BioRad MRC-1024 confocal laser-scanning microscope
(Carl Zeiss Pty. Ltd. North Ryde, NSW, Australia) was
used to examine immunofluorescence with filter settings
for identification of secondary antibody fluorophores
(fluorescein isothiocyanate [FITC], cyanine [CY2] and in-
docarbocyanine [CY3]). Each fluorochrome was viewed
separately in single channel mode and no ‘‘bleed through’’
was observed. To excite FITC labelled and CY2 secondary
antibodies, excitation was set at 488 nm, while 568 nm
excitation was used for CY3. Images were captured by
taking 4–6 optical ‘‘slices’’ through the sections as a ‘‘z’’
series imaging 10–30 microns of tissue, and then recon-
structed as a single two-dimensional image using Confocal
Assistant Software (BioRad). Figures were assembled and
labelled using Photo Shop software (version 6, Adobe
Systems, Mountain View, CA). Overall colour balance and
contrast were adjusted, but no other modifications were
made.
Results
Detection of cGMP-IR in the RVLM
Cells expressing either the adrenergic markers PNMT/TH,
or nNOS, were used to delineate the neuronal populations
J Biomed Sci (2008) 15:801–812 803
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of interest within the RVLM. PNMT/TH neurons defined
the rostro-caudal axis of the C1 adrenergic cell group while
nNOS cell bodies bounded the medial RVLM region [29].
In the first series of experiments, sections from mature
WKY (n = 4) and SHR (n = 4) ([18 weeks) were
examined for double labelling for cGMP/PNMT-IR and
cGMP/nNOS-IR. Results showed very few cGMP immu-
noreactive neurons in the RVLM in association with either
the C1 adrenergic or the nNOS cells groups in either strain
of mature animal and no cells were double labelled for
either cGMP:PNMT or cGMP:nNOS (Fig. 1a–f). There
was strong cGMP-IR in the NA (Fig. 1b, f) and in these
cells, staining was punctate in appearance, and localised to
the cytoplasm and extending neurites. Cyclic GMP-IR was
visible in the vasculature throughout the sections.
To control for rapid degradation of cGMP, in the second
series of experiments, additional adult WKY (n = 4) and
SHR (n = 2) were assessed after perfusion with IBMX
(0.5 mM) in the pre-perfusate solution. Double labelling
was performed for cGMP and either PNMT/TH or nNOS.
The presence of IBMX did not reveal any increase in the
number of cGMP-IR neurons in the RVLM and did not
alter the PNMT, TH or nNOS-IR (data not shown). There
was a visible increase in the intensity of staining for cGMP
in cells of the NA and within blood vessels of the RVLM
region in both the WKY and SHR (Fig. 2). To assess the
influence of animal age, in the third series of experiments,
immunohistochemistry for cGMP/PNMT was performed in
young male WKY animals (10 weeks; n = 3). The pattern
of immunoreactivity was the same as that seen in the adult
WKY, with very few cells outside of the NA showing
cGMP-IR above the level of background in the RVLM
region (data not shown).
Detection of cGMP-IR in brainstem slices after
incubation in-vitro
In the fourth series of experiments, cGMP-IR in the RVLM
was examined in brainstem slices that were treated in-vitro
using experimental paradigms designed to increase cGMP
synthesis. Due to the extended time frame of the experi-
mental protocol, all experiments were performed in the
presence of IBMX (0.5 mM). Sections were examined after
incubation of brainstem slices in-vitro in aCSF (control),
with 100 lM NMDA or the NO donor DETA-NO
(100 lM; n = 3 for each experiment, total n = 9 WKY
10 week-old animals). In the aCSF control experiments,
the location of neuronal cGMP staining was comparable
with that from the fixation perfused experiments (Fig. 3a,
b). However, tissue integrity and overall fluorescence was
reduced in this series of experiments due to the incubation
protocol and the requirement for cryoprotection prior to
sectioning. In those brainstem slice preparations incubated
with NMDA (Fig. 3c, d) or DETA-NO (Fig. 3e, f), the
cGMP staining in the vasculature and NA was brighter
when compared to control (aCSF) preparations (inset
panels b0, d0 and f0), but no additional neuronal staining in
RVLM neurons was uncovered (Fig. 3).
Table 1 Primary and secondary antibodies: dilutions and source
Antigen and host species Dilution Product code and source
Primary detection antibodies
Anti cGMP: Rabbit polyclonal 1:500 AB303: Chemicon (Temecula CA, USA)
Anti nNOS: Mouse monoclonal 1:400 N2280: Sigma (St. Louis, MO, USA)
Anti PNMT: Sheep polyclonal 1:500 AB146: Chemicon
Anti TH: Mouse monoclonal 1:300 22941: Clone LNC1, Immunostar (Hudson, Wisconsin, USA)
Anti sGC (b1-subunit): Rabbit polyclonal 1:500 160897: Cayman Chemicals (Ann Arbour, MI USA)
Anti PGP9.5: Guinea pig polyclonal 1:750 AB5898: Chemicon
Anti GFAP: Mouse monoclonal 1:750 G3893, clone G-A 5: Sigma
Anti alpha-SMA: Mouse monoclonal 1:500 A5228, clone 1A4: Sigma
Secondary detection antibodies
FITC: Donkey anti-mouse IgG 1:500 Jackson (West Grove, PA)
CY2: Donkey anti-sheep IgG 1:500 Jackson
CY3: Donkey anti-rabbit IgG 1:500 Jackson
CY3: Donkey anti-guinea pig IgG 1:750 Jackson
CY3: Donkey anti-mouse IgG 1:750 Jackson
Cyclic guanosine monophosphate (cGMP); neuronal nitric oxide synthase (nNOS), phenylethanolamine N-methyltransferase (PNMT), tyrosine
hydroxylase (TH), soluble guanylate cyclase (sGC), Protein Gene Product-9.5 (PGP9.5), Glial fibrillary acidic protein (GFAP), alpha-Smooth
Muscle Actin (alpha-SMA), fluorescein isothiocyanate (FITC), cyanine (CY2), indocarbocyanine (CY3)
804 J Biomed Sci (2008) 15:801–812
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Detection of sGC-IR in the RVLM
In the fifth series of experiments, sections from WKY
animals (10 weeks, n = 3) were examined for sGC/PNMT
and sGC/nNOS-IR. Within the RVLM region, sGC-IR was
widely distributed and unlike the PNMT and nNOS-IR
neuronal populations, sGC cells did not localise to a dis-
tinct group or nuclei. Cells immunoreactive for sGC were
often in close proximity to PNMT (Fig. 4a) or nNOS
immunoreactive cells (data not shown) but there was no co-
localisation.
The sixth and final series of experiments were under-
taken in order to confirm the neuronal expression of sGC.
Sections from WKY animals (10 weeks, n = 3) were
double labelled for sGC and PGP-9.5 (neuronal specific
marker). Parallel control experiments double labelling for
Fig. 1 Confocal images
depicting double labelling for
PNMT/cGMP (a, b) and nNOS/
cGMP (c, d) in the RVLM of
adult WKY in the absence of
IBMX, and PNMT/cGMP (e, f)
in the RVLM of an adult SHR in
the absence of IBMX. PNMT-
immunoreactivity (a, e)
indicates the location of the C1
adrenergic cell group. Panel (c)
illustrates nNOS
immunoreactive cells, located
adjacent to the inferior olive
(IO) in the ventromedial region
of the RVLM. cGMP-IR in the
neurons of the NA and in blood
vessels (arrows) is evident
(panels b, d, f) however there is
no labelling of neurons with
cGMP in association with either
the PNMT or nNOS cell groups.
A single cGMP-IR neuron is
visible (arrow head, panel f) in
the C1 region of the SHR
animal. Scale bar in Panel
(b) = 200 lm for panels (a, b).
Scale bars in panels (d) and (f)
equal 100 lm for panels (c, d)
and (e, f), respectively
J Biomed Sci (2008) 15:801–812 805
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sGC and a non-neuronal cell (astroglia: marker GFAP)
were also performed. The cellular staining pattern for
GFAP was consistent with the morphology and distribution
of astroglia [40], and showed no colocalisation or pattern
similarity to the sGC staining (Fig. 4b). In contrast, all cells
showing sGC-IR were consistently double labelled with
PGP9.5, confirming that sGC was expressed in neurones in
the RVLM (Fig. 4c). Additional experiments in adult SHR
(n = 2) showed the same expression pattern of sGC in
PGP9.5-IR cells (data not shown).
Control experiments
Sections processed in the absence of primary antibody did
not show any staining (Fig. 5a). Control experiments for
sGC in the cerebellum showed the typical sGC-IR staining
(Fig. 5b) as previously described by Ding et al [41].
Positive controls for PGP9.5 using a TH double label
showed that all TH-IR neurons from the RVLM region also
expressed PGP9.5-IR, in addition to adjacent neurons that
expressed PGP9.5 only (Fig. 5c). Double labelling with
alpha-SMA, which labels smooth muscle cells of precap-
illary arterioles in the brain [42], showed co-localisation
with cGMP (Fig. 5d). Furthermore, our overall pattern of
vascular/microvascular cGMP staining in the brain is as
described by [31].
Discussion
It is well documented that the premotor sympathetic neu-
rons in the RVLM are critical to the maintenance and
control of blood pressure [43] and that endogenous NO is
an important mediator in this regulatory process [9, 10, 21].
Functional studies provide strong evidence that NO acts
through the sGC-cGMP signalling pathway in the RVLM
to drive sympathoexcitatory responses [6, 20, 44, 45],
however, we were unable to detect cGMP in the RVLM of
either the SHR or WKY rat strains. This was despite the
use of PDE inhibitors of the use of specific stimulators of
cGMP synthesis in slice preparations. We were able to
demonstrate abundant sGC-IR in neurones throughout the
RVLM region.
Cyclic GMP in the RVLM
An inability to detect cGMP in the RVLM may have been
associated with methodological issues, for example the
adequacy of antigen recognition/penetration, or sensitivity
of the technique. These concerns are alleviated somewhat
by our detection of cGMP in the adjacent brainstem region
of the NA. Alternative methodologies such as radioim-
munoassay may have been more sensitive, however the
ability to define specific neuronal populations is lost and in
a study examining hippocampal slices, analysis of cGMP
radioimmunoassay versus cGMP immunofluorescence
intensity showed comparable sensitivities [46]. The lack of
detectable cGMP expression in neurons of the RVLM is in
accord with a detailed study by De Vente et al. [22], who
similarly observed cGMP in the NA and nucleus tractus
solitarii (NTS) in the brain stem region, but do not com-
ment on its expression in the RVLM, despite the use of in-
vitro stimulation paradigms as applied in this study. In the
work by De Vente et al., the importance of IBMX to reveal
Fig. 2 Confocal images illustrating cGMP in RVLM sections taken
from adult WKY (a) and SHR (b) animals treated with IBMX in the
pre-perfusate solution. Midline is located to the left and ventral
surface of the medulla towards the base. Figures show the marked
increase in detection of cGMP in the vasculature (arrows) and cells of
the NA when compared to Fig. 1, however very few neurons
expressing cGMP were detected in the RVLM region. Individual
neurons showing cGMP-IR above the level of background staining
are shown (arrow heads). Scale bar in (a) equals 200 lm, scale bar in
panel (b) equals 100 lm
806 J Biomed Sci (2008) 15:801–812
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otherwise non-detectable cGMP populations was stressed
[22, 47] and this has also been noted by other authors [48].
For this reason, IBMX was used in a subset of studies in
perfusion fixed rats and for the brainstem slice in-vitro
incubation experiments. However, while we found that
IBMX did increase the levels of cGMP in already visible
cell populations and in the vasculature of the brainstem, it
did not uncover cGMP-IR neurons in the RVLM,
suggesting IBMX-sensitive PDE activity did not limit
detection. This concurs with our previous work examining
cGMP levels in the spinal cord, where we were able to
show that cGMP expressing sympathetic preganglionic
neurons could be readily detected in the absence of IBMX
[30]. The effects of anaesthetic on cGMP levels also
require consideration. For this project, anaesthetic was an
ethical requirement. Results from studies investigating the
Fig. 3 Confocal images
depicting cGMP (b, d, e) and
either PNMT (a, c) or nNOS-IR
(e) in RVLM sections from
WKY rats after treatment in-
vitro to increase cGMP




(c) and (d) illustrate PNMT/
cGMP-IR respectively after in-
vitro incubation in NMDA
(100 lm 2 min). Panels (e and
f) show nNOS/cGMP-IR,
respectively after incubation in
DETA-NO (100 lm 15 min).
Insets b0, d0 and f0 illustrate
cGMP expression in the NA
under control, NMDA and
DETA-NO experimental
conditions, respectively. All
experiments were performed in
the presence of 0.5 mM IBMX.
Despite cGMP-IR in blood
vessels (arrows) and NA being
enhanced by the in-vitro
treatments, they failed to reveal
the presence of additional
cGMP-IR neurons in the RVLM
regions in association with
either the PNMT or nNOS cell
groups. Scale bar in (f) equals
100 lm for panels (a–f). Scale
bar in f0 equals 100 lm for
panels (b0, d0 and f0)
J Biomed Sci (2008) 15:801–812 807
123
effect of anaesthetic on cGMP in the central nervous sys-
tem are conflicting, with some reports describing the
effects of anaesthetics as inhibitory, while others suggest
no effect or indeed an increase in cGMP levels [49]. Thi-
opentone was chosen for this study on the rationale that
intravenous agents are less likely to depress cGMP levels
than inhalation anaesthetics [50], and that pentobarbital
drugs specifically do not depress cGMP levels in the
brainstem [51]. Given the time period available for
anaesthetic washout and the demonstration of an increase
of detectable cGMP in surrounding tissues, it is likely the
effects of anaesthetic were minimal in this study.
The use of NMDA and NO donors to increase detectable
cGMP in brain slice in-vitro preparations has been dem-
onstrated previously in various tissues including the
paraventricular nucleus [52] cerebellum [22, 47] and hip-
pocampus and thalamus [46]. The choice of DETA-NO as a
donor was based on its ability to spontaneously liberate NO
in aqueous solutions in a stable, time-controlled fashion
[53]. It has been proposed that the type of NO donor can
make a significant difference to the way in which cGMP is
stimulated [54], however a recent study comparing the
effects of NONOates to the classical NO donor sodium
nitroprusside found limited difference in their ability to
stimulate sGC or influence cGMP staining patterns in brain
slice preparations [46]. The NO donor nitroglycerin has also
been shown to increase cGMP-IR in both neuronal and
vascular elements of the brain, but in agreement with our
study, did not uncover any additional or previously unde-
tected cGMP immunoreactive neuronal cell groups [31].
Soluble guanylate cyclase expression within the RVLM
The widespread detection of sGC within neurones of the
RVLM is in accord with previous studies that have dem-
onstrated both mRNA and protein for sGC within the
medulla [55, 56]. It is likely to be a functional form of sGC,
as the antibody we used was specific for the b1 subunit,
which is the obligatory subunit for functional sGC [15],
Fig. 4 Confocal images illustrating double labelling for PNMT/sGC
(a), GFAP/sGC (b) and PGP9.5/sGC (c) immunoreactivity in the
RVLM from a WKY animal (male, 10-weeks-old). Panel (a) shows
PNMT (red—CY3 secondary antibody) and sGC (green—FITC
secondary antibody) double labelling and illustrates numerous cells
IR for sGC (arrows) but lack of co localisation with PNMT (#). Panel
(b) shows GFAP (red—CY3 secondary antibody) and sGC (green—
FITC secondary antibody) and serves to demonstrate that the cells
immunoreactive for sGC (arrows) show none of the characteristic
morphological features of astrocytes (*) and that there is no double
labelling for the two markers. Panel (c) shows PGP9.5 (red—CY3
secondary antibody) and sGC (green—FITC secondary antibody) and
illustrates double labelling for all sGC cells (arrows; yellow), with
adjacent neurons immunoreactive for PGP9.5 only (*). Scale bar in
(a) equal 100 lm, scale bar in panels (b) and (c) equals 50 lm
c
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and has been shown to co-localise extensively with the a
subunit throughout the CNS of the adult rat brain [41].
While we did not demonstrate co-localisation of sGC
with the nNOS cell population, they were often in close
association. This pattern of expression is consistent with
other brain regions, where NO responsive and NO pro-
ducing structures are not found within the same neuronal
profile [22, 41, 57]. An exception is the NTS, where nNOS
and sGC have been shown to co-localise [58]. Similarly,
we saw sGC in close association but not co-localised with
the C1 cell group. Additional studies aimed at determining
the cell population which expresses sGC should include
retrograde labelling as a means of identification of the non-
C1 bulbospinal group [2], and double labelling for markers
such as neuropeptide Y to identify neurons which project to
the hypothalamus [59], or markers to enable identification
of glutamatergic and gabaergic neurons [3]. This would
then allow potential functional relevance to be attributed to
sGC expression in the region.
Conclusion
A number of physiological studies indicate that NO can
modulate pressor and reflex responses in the RVLM via an
sGC/cGMP dependent mechanism [6, 7, 44, 45]. While we
Fig. 5 Control experimental results. Panel (a) shows a negative
control for PGP9.5 (red—CY3 secondary antibody) and sGC
(green—FITC secondary antibody). Double labelling on a control
RVLM section from a 10-week-old WKY shows no immunoreactivity
for either series of labelling reactions. Panel (b) shows intense
labelling for sGC (red—CY3 secondary antibody) in the cerebellum
from a 10 week old WKY. Panel (c) shows positive control
experiments for PGP9.5 from an adult SHR animal. All TH positive
cells (green—FITC secondary antibody) were double labelled for
PGP9.5 (red—CY3 secondary antibody) resulting in a yellow colour
on the overlaid images (arrows). Immediately adjacent to the double-
labelled cells are PGP9.5 only labelled neurons (*). Panel (d) shows
control experiments assessing the vascular expression of cGMP in a
10 week old WKY. Sections were double labelled for alpha-smooth
muscle actin (alpha-SMA; green—FITC secondary antibody) and
cGMP (red—CY3 antibody). All alpha-SMA-IR structures showed
clear co-localisation with cGMP as illustrated. The cGMP expression
can be seen to extend from the larger precapillary arteriole (arrows) to
the microvasculature, where it is expressed in pericytes (the
contractile elements of the brain microvasculature) that do not label
for alpha-SMA [64, 65]. Scale bar in (a) equal 50 lm, scale bar in
panels (b) and (c) equal 100 lm, scale bar in panel (d) equals 20 lm
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were unable to detect cGMP-IR in the neurons of the C1
region, either in the resting state, when stimulated by
NMDA or NO donor, or after PDE inhibition, our sGC-IR
results certainly indicate the capacity for cGMP synthesis.
In an in-vivo study of the cat, nNOS-sGC co-localisation
was present in the RVLM only after activation by brady-
cardia (as identified by the presence of c-fos) [60]. This
raises the hypothesis that functional network inputs, such
as the sympathetic baroreflex pathway [45] are required to
drive a sGC/cGMP cascade in the RVLM. This may be the
mechanism by which functional differences in the SHR and
WKY are delineated and future studies investigating this
possibility are warranted.
Basal cGMP levels in neurons are the result of a
dynamic equilibrium between synthesis, driven by NO-
sGC, and the rate of degradation by PDEs, [61]. The rate of
synthesis can change with time due to desensitisation of
sGC, and cGMP kinetics can vary between not only dif-
ferent cell types but also different regions of the brain [62].
The expression of IBMX-insensitive PDEs, such as PDE9,
which is specific for cGMP [46, 63], may be another
important factor limiting detection of cGMP accumulation
in regions such as the RVLM. Of note is a recent study that
has shown under similar conditions to ours, that the use of
an NO donor in the presence of IBMX was not sufficient to
maximise cGMP detection in the hippocampus, but instead
required the further addition of the NO-independent acti-
vators of sGC: YC-1 or BAY 41-2272 [46]. This stimulated
cGMP synthesis in cells not normally known to express
cGMP and the authors suggest the presence of an endog-
enous sGC inhibitor as a possible explanation [46].
Examination of the role of functional stimulatory inputs,
NO-independent activation of sGC and the activity of
specific PDEs is therefore required before the definitive
role of cGMP as a contributor to altered sympathetic tone
in the SHR can be ascertained.
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